Verastem (VSTM) Stock Analysis & Winston Score

Verastem is a small biotechnology company that develops cancer drugs. Its main product is Avutometinib plus Defactinib, a combination therapy targeting a type of ovarian cancer called low-grade serous ovarian cancer (LGSOC). The company sells to oncologists and cancer treatment centers, primarily in the United States, and received FDA approval for this combination in 2024 under the brand name AVMAPKI FAKZYNJA Co-pack. Verastem makes money by selling its approved drug to hospitals and specialty pharmacies. It operates almost entirely in the US and is a small commercial-stage company with a market cap around $500 million. The gross margin is positive, but the company spends far more than it earns, resulting in deep operating losses — a common situation for newly commercial biotechs. The key growth driver is expanding the use of its drug into additional cancer types, while the main risk is whether it can grow revenue fast enough to stop burning through cash.